Bright light therapy improves cancer-related fatigue in cancer survivors: a randomized controlled trial
Cancer-related fatigue (CRF) is a common and distressing symptom that can persist after cancer treatment has concluded. Bright light therapy has shown preliminary efficacy in reducing CRF, but its impact on other psychosocial factors is unclear. The purpose was to examine the impact of a 1-month light therapy intervention on fatigue, mood, and quality of life in cancer survivors with fatigue.
This 4-week blinded randomized controlled trial recruited cancer survivors who met diagnostic criteria for CRF. Participants were randomly assigned to receive a light therapy device that produced either bright white light (BWL; intervention) or dim red light (DRL; active control). Participants were instructed to use the device daily for 30 min upon waking for 28 days. The primary outcome, fatigue, was assessed weekly. Secondary outcomes assessed pre- and post-intervention included mood, depressive symptoms, and quality of life.
A total of 81 participants were randomly assigned to receive BWL (n = 42) or DRL (n = 39). Analyses revealed a group-by-time interaction for fatigue (p = .034), wherein the BWL condition reported a 17% greater reduction in fatigue than those in the DRL condition (between group d = .30). There were also significant improvements over time for both groups on measures of mood, depressive symptoms, and quality of life (p’s < .01).
BWL was associated with greater improvements in fatigue and both groups displayed improvements on secondary psychosocial outcomes.
Implications for cancer survivors
These findings, along with previous reports of light therapy for CRF, support the use of this intervention to improve fatigue in cancer survivors.
KeywordsCancer-related fatigue Fatigue Light therapy Cancer Quality of life Randomized controlled trial
We would like to acknowledge and thank each participant who dedicated their time to be involved in this study. J.A. Johnson would like to acknowledge the following funding agencies for graduate training support: Alberta-Innovates Health Solutions, the Alberta Cancer Foundation, the Killam Trust, and Lloyd and Florence Cooper Trust.
Compliance with ethical standards
Conflict of interest
T.S. Campbell discloses speaker’s honoraria from Abbvie, Janseen, Lifescan, NovoNorodisk and research funding from Abbvie. S. Ancoli-Israel consults for Merck, Pfizer, Ferring, and Janssen.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 3.Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32:1840–50.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Prog. Neuro-psychopharmacology. Biol Psychiatry. 2011;35:1569–74.Google Scholar
- 17.Johnson JA, Garland SN, Carlson LE, Savard J, Simpson JSA, Ancoli-Israel S, et al. The LITE study: rationale and protocol for a randomized controlled trial of light therapy for cancer-related fatigue in cancer survivors. Contemp Clin Trials. 2016;Google Scholar
- 24.Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 1999;46:437–443.Google Scholar